Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130264 | 0.93 | KIF11 (0.86) | KIF11EPHX2CA1CA2 | |
| Iodide SCHEMBL29203651 | 0.91 | KIF11 (0.83) | KIF11EPHX2CA1CA2 | |
| Hydrochloric Acid SCHEMBL27956162 | 0.91 | KIF11 (0.83) | KIF11EPHX2CA1CA2 | |
| Hydrochloric Acid SCHEMBL27956160 | 0.91 | KIF11 (0.83) | KIF11EPHX2CA1CA2 | |
| SCHEMBL22270553 | 0.83 | KIF11 (0.70) | KIF11EPHX2 | |
| SCHEMBL1921452 | 0.81 | KIF11 (0.68) | KIF11EPHX2CA1CA2 | |
| SCHEMBL19822993 | 0.81 | KIF11 (0.68) | KIF11EPHX2CA1CA2 | |
| SCHEMBL12969077 | 0.81 | KIF11 (0.67) | KIF11EPHX2 | |
| SCHEMBL16676705 | 0.81 | KIF11 (0.67) | KIF11 | |
| SCHEMBL29914837 | 0.80 | KIF11 (0.78) | KIF11CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103261165-A | Glucagon receptor modulators | PFIZER | 2013-08-21 | — | — | CN | disclosed |
| US-20070265345-A1 | Novel Biphenyl Compounds And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1465613-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| WO-2003057205-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-07-17 | — | — | WO | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004020-A1 | HETEROARYL CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265345-A1 | Novel Biphenyl Compounds And Their Use | KIF5B, KIF5C, KIF5A | KIF11 8/4885EPHX2 2481/4885CA1 4737/4885 |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | KIF11 2572/4885EPHX2 2438/4885CA1 4884/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | KIF11 4744/4885EPHX2 663/4885CA1 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.